The use of variations in proteomes to predict, prevent, and personalize treatment for clinically nonfunctional pituitary adenomas.
The use of variations in proteomes to predict, prevent, and personalize treatment for clinically nonfunctional pituitary adenomas.
复制标题
DOI：
10.1007/s13167-010-0028-z
复制
发表时间：
2010-09
期刊：
影响因子：
6.5
通讯作者：
Desiderio, Dominic M
中科院分区：
文献类型：
--
作者：
Zhan, Xianquan;Desiderio, Dominic M
垂体腺瘤占颅内肿瘤的0.10%，它们会导致附近结构的压迫和垂体激素的不适当表达。与功能性垂体腺瘤不同，非功能性（NF）垂体腺瘤占垂体瘤的约30%，并且大到足以致盲;因为它们不会引起任何临床激素分泌过多，所以难以在早期发现;并且导致垂体功能减退。没有有效的分子生物标志物或化学治疗已被批准用于临床环境。由于NF垂体腺瘤是高度异质性的，蛋白质（蛋白质组）的差异可以区分这些异质性结构。随着NF腺瘤的进展，蛋白质组的组分动态变化。蛋白质表达和蛋白质修饰的变化，单独或组合，可能是预测疾病，监测肿瘤进展，并为个性化患者治疗开发准确的分子分类的生物标志物。蛋白质组学变异的模式也可能有助于对患者进行干预性预防和个性化治疗，以阻止NF垂体腺瘤的发生和进展。
Pituitary adenomas account for ∼10% of intracranial tumors, and they cause the compression of nearby structures and the inappropriate expression of pituitary hormones. Unlike functional pituitary adenomas, nonfunctional (NF) pituitary adenomas account for ∼30% of pituitary tumors, and are large enough to cause blindness; because they do not cause any clinical hormone hypersecretion, they are difficult to detect at an early stage; and hypopituitarism results. No effective molecular biomarkers or chemical therapy have been approved for the clinical setting. Because an NF pituitary adenoma is highly heterogeneous, differences in the proteins (the proteome) can distinguish among those heterogeneity structures. The components of a proteome dynamically change as an NF adenoma progresses. Changes in protein expression and protein modifications, individually or in combination, might be biomarkers to predict the disease, monitor the tumor progression, and develop an accurate molecular classification for personalized patient treatment. The modalities of proteomic variation might also be useful in the interventional prevention and personalized treatment of patients to halt the occurrence and progression of NF pituitary adenomas.